- Frailty is significantly associated with worse OS in patients with NSCLC who undergo stereotactic body radiotherapy (SBRT).
Why this matters
- A modified frailty index (mFI) could help better stratify risk and treatment planning.
- 140 patients with early-stage NSCLC treated with SBRT.
- mFI criteria of ≤2 as nonfrail and >2 as frail.
- Funding: None disclosed.
- 72.9% of the patients were aged >70 years.
- 56.4% had adenocarcinoma; 55.0% with stage T1aN0.
- 35.0% were frail and those patients were older (87.8% vs 64.8% >70 years; P=.007).
- Median OS was 65.9 months, but median OS for frail patients was 58.7 months.
- Frail patients had significantly worse OS compared with nonfrail patients (P=.01), with a 3-year OS of 59.3% vs 82.0% in nonfrail patients.
- Local control (P=.02) and distant control (P=.03) were significantly worse in the frail group (3-year local control 85.3% vs 97.0% and 3-year distance control 80.6% vs 93.4%, respectively).
- Recurrence-free survival was significantly worse in frail patients (P=.01), with overall RFS at 3 years of 67.3% (53.4% in frail and 74.5% in nonfrail patients).
- After multivariable analysis, frailty was significantly associated with worse OS (HR, 1.98; 95% CI, 1.02-3.85).
- Single-center, retrospective study.